40 mg lyophilised · single compound
$170.00 CAD
MOTS-c is a peptide that the body's own mitochondria produce, studied in metabolism research. Laboratory work explores its role in how cells use energy and respond to insulin and exercise.
For laboratory and research use only - not for human consumption.
Checking the live COA archive for the newest lot documentation.
Use the verification archive to select a peptide name and review all published lot records alphabetically.
View previous lab resultsMOTS-c is a 16-amino-acid “mitochondrial-derived peptide.” Unusually, it is encoded inside mitochondrial DNA (the small separate genome of the mitochondria, the cell’s energy “power plants”) rather than in the main nuclear genome.
In the landmark 2015 study, MOTS-c improved insulin sensitivity and protected mice from diet-induced obesity and insulin resistance. It is studied in metabolism, AMPK signalling (a cellular “energy sensor”), and exercise research.
MOTS-c acts largely on skeletal muscle, influencing the folate cycle and purine synthesis in a way that activates AMPK (the master energy-balance switch); it can also move into the cell nucleus to adjust gene expression under metabolic stress.
MOTS-c is not an approved medicine in any jurisdiction, and this product is supplied as a research compound only. In July 2026 a US FDA advisory committee voted 7-5 to recommend MOTS-c for the American 503A compounding list, having reviewed it for obesity and osteoporosis and against the recommendation of the FDA's own scientific reviewers. That vote is advisory and not binding: it concerns what US compounding pharmacies may work with, it is not a drug approval, and it takes effect only if the FDA accepts it and completes formal rulemaking.
A single vial containing 40 mg of MOTS-c as a lyophilised powder.
